Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 57

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 57
---
5,896 International374 462 1,129 1,415 Total$993 $2,227 $3,294 $7,311 NeuroscienceVraylarUnited States$931 $873 $2,592 $2,338 International3 2 7 5 Total$934 $875 $2,599 $2,343 Botox TherapeuticUnited States$825 $708 $2,323 $1,988 International160 140 456 422 Total$985 $848 $2,779 $2,410 UbrelvyUnited States$344 $261 $907 $685 International10 8 25 18 Total$354 $269 $932 $703 QuliptaUnited States$252 $168 $661 $442 International36 8 87 15 Total$288 $176 $748 $457 VyalevUnited States$53 $— $81 $— International85 28 218 55 Total$138 $28 $299 $55 DuodopaUnited States$16 $24 $56 $72 International80 87 233 267 Total$96 $111 $289 $339 Other NeuroscienceUnited States$42 $54 $148 $172 International4 2 12 11 Total$46 $56 $160 $183 

2025 Form 10-Q | 24

Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2025202420252024OncologyImbruvicaUnited States$507 $618 $1,579 $1,823 Collaboration revenues199 210 619 676 Total$706 $828 $2,198 $2,499 VenclextaUnited States$341 $340 $974 $921 International385 337 1,108 1,007 Total$726 $677 $2,082 $1,928 ElahereUnited States$150 $139 $453 $331 International20 — 55 — Total$170 $139 $508 $331 EpkinlyColl